Exametazime Pregnancy and Breastfeeding Warnings
Brand names: Ceretec, Drax Exametazime
Exametazime Pregnancy Warnings
FDA pregnancy category: C
Potential benefit should outweigh the potential risk.
Animal reproduction studies have not been conducted.
It is not known whether Tc99m exametazime can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity.
FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Exametazime Breastfeeding Warnings
Breast-feeding is not recommended during use of exametazime.
Excreted into human milk: Yes (technetium Tc99m); unknown (exametazime)
Excreted into animal milk: Unknown
The effects in the nursing infant are unknown.
The manufacturer recommends formula feedings for 60 hours following administration.
See also
References for pregnancy information
- (2012) "Product Information. Ceretec (exametazime)." GE Healthcare
References for breastfeeding information
- (2012) "Product Information. Ceretec (exametazime)." GE Healthcare
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.